Circuit 2 : IVTV - Episkin

Culture

Episkin is an in vitro reconstructed human epidermis from normal human
keratinocytes cultured on a collagen matrix at the air-liquid interface. This model is histologically similar to the in vivo human epidermis.
The human keratinocytes come from mammary samples obtained from healthy consenting donors during plastic surgery. HIV 1 & 2, B and C hepatitis tests are carried out on the donor bloods as well as verification of the bacteriological & fungal sterility of the cells and absence of mycoplasma.

Reproductibility
EpiSkin is produced in accordance with the quality reference norm ISO 9001, ensuring traceability and reproducibility of the epidermal tissues.
The reproducibility of each batch is checked by histological analysis taking into account the general organisation, the stratification of the epidermis, the nucleation of the basal layer, the size of the intercellular spaces, adhesion of the basal layer to the support, the quantity of granular cells and the thickness of the horny layer. Each criterion is scored from 0 to 4. The maximum score is 28. The minimum score for histology acceptability of the model is 19/28.
The reproducibility of the response of each EpiSkin batch is tested against a reference irritant: SDS. The IC50 of the surfactant is measured by the MTT assay after 18 hours of contact. The minimum score for acceptability of the model is icso ≥ 1mg/ml.

Le projet d'Equipements d'EXcellence Ingénierie et Vieillissement des Tissus Vivants choisi par le Ministère de l'Enseignement Supérieur et de la Recherche, est un projet unique en Europe et de grande envergure qui va naître sur l'ECL et le CHU de Saint-Etienne.
Ce projet permettra la création d'une plateforme dotée d'outils innovants sur l'étude du vieillissement des tissus humains. Pour la première fois une double approche scientifique sera menée en biologie et en mécanique, elle visera à l'amélioration de la santé des citoyens par le développement de nouvelles solutions thérapeutiques..
Voir le site de l'IVTV    

Aucun commentaire:

Enregistrer un commentaire